Ramahi Ahmad, Heider Amer, Kahlenberg J Michelle
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48103, USA.
Department of Pathology, University of Michigan, Ann Arbor, MI 48103, USA.
Case Rep Rheumatol. 2022 Sep 26;2022:6503453. doi: 10.1155/2022/6503453. eCollection 2022.
Systemic lupus erythematosus (SLE) is an autoimmune, chronic, and heterogenous disease with organ damage resulting from immune complex deposition and inflammatory infiltrates. Antimalarial drugs, such as hydroxychloroquine (HCQ), are cornerstone immunomodulators for the treatment of SLE. Rarely, HCQ toxicity can occur, leading to devastating outcomes. We report a case of a patient with SLE on HCQ who presented with a rapid onset of large pericardial effusion and a dramatically decreased left ventricular ejection fraction. Endomyocardial biopsy was positive for curvilinear bodies, confirming the diagnosis of hydroxychloroquine cardiotoxicity. Hydroxychloroquine cardiomyopathy is a rare but life-threatening medication side effect. It is important to consider it in any patient taking the medication who presents with a new onset or worsening symptoms of heart failure.
系统性红斑狼疮（SLE）是一种自身免疫性、慢性且异质性疾病，因免疫复合物沉积和炎症浸润导致器官损害。抗疟药物，如羟氯喹（HCQ），是治疗SLE的基础免疫调节剂。HCQ毒性罕见，但可导致严重后果。我们报告一例服用HCQ的SLE患者，该患者迅速出现大量心包积液且左心室射血分数显著降低。心内膜活检发现曲线小体阳性，确诊为羟氯喹心脏毒性。羟氯喹心肌病是一种罕见但危及生命的药物副作用。对于任何服用该药物且出现新发或加重心力衰竭症状的患者，都应考虑到这一点。
